|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: UFL1 |
Gene summary for UFL1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | UFL1 | Gene ID | 23376 |
| Gene name | UFM1 specific ligase 1 | |
| Gene Alias | KIAA0776 | |
| Cytomap | 6q16.1 | |
| Gene Type | protein-coding | GO ID | GO:0001101 | UniProtAcc | O94874 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 23376 | UFL1 | LZE4T | Human | Esophagus | ESCC | 1.27e-15 | 5.12e-01 | 0.0811 |
| 23376 | UFL1 | LZE7T | Human | Esophagus | ESCC | 2.77e-02 | 4.03e-01 | 0.0667 |
| 23376 | UFL1 | LZE8T | Human | Esophagus | ESCC | 6.64e-07 | 2.02e-01 | 0.067 |
| 23376 | UFL1 | LZE20T | Human | Esophagus | ESCC | 1.17e-03 | 1.98e-01 | 0.0662 |
| 23376 | UFL1 | LZE24T | Human | Esophagus | ESCC | 1.36e-11 | 4.11e-01 | 0.0596 |
| 23376 | UFL1 | LZE21T | Human | Esophagus | ESCC | 2.69e-04 | 3.14e-01 | 0.0655 |
| 23376 | UFL1 | P1T-E | Human | Esophagus | ESCC | 1.97e-08 | 5.40e-01 | 0.0875 |
| 23376 | UFL1 | P2T-E | Human | Esophagus | ESCC | 1.54e-39 | 8.06e-01 | 0.1177 |
| 23376 | UFL1 | P4T-E | Human | Esophagus | ESCC | 4.33e-29 | 6.27e-01 | 0.1323 |
| 23376 | UFL1 | P5T-E | Human | Esophagus | ESCC | 1.08e-20 | 4.64e-01 | 0.1327 |
| 23376 | UFL1 | P8T-E | Human | Esophagus | ESCC | 3.25e-32 | 5.92e-01 | 0.0889 |
| 23376 | UFL1 | P9T-E | Human | Esophagus | ESCC | 1.72e-08 | 2.53e-01 | 0.1131 |
| 23376 | UFL1 | P10T-E | Human | Esophagus | ESCC | 5.17e-30 | 5.84e-01 | 0.116 |
| 23376 | UFL1 | P11T-E | Human | Esophagus | ESCC | 3.79e-17 | 7.24e-01 | 0.1426 |
| 23376 | UFL1 | P12T-E | Human | Esophagus | ESCC | 5.28e-38 | 7.66e-01 | 0.1122 |
| 23376 | UFL1 | P15T-E | Human | Esophagus | ESCC | 1.26e-14 | 3.98e-01 | 0.1149 |
| 23376 | UFL1 | P16T-E | Human | Esophagus | ESCC | 1.92e-55 | 9.89e-01 | 0.1153 |
| 23376 | UFL1 | P17T-E | Human | Esophagus | ESCC | 2.87e-04 | 3.69e-01 | 0.1278 |
| 23376 | UFL1 | P20T-E | Human | Esophagus | ESCC | 2.38e-17 | 3.49e-01 | 0.1124 |
| 23376 | UFL1 | P21T-E | Human | Esophagus | ESCC | 1.48e-35 | 6.85e-01 | 0.1617 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:004217622 | Liver | HCC | regulation of protein catabolic process | 267/7958 | 391/18723 | 2.45e-25 | 7.38e-23 | 267 |
| GO:003497612 | Liver | HCC | response to endoplasmic reticulum stress | 189/7958 | 256/18723 | 1.43e-24 | 4.06e-22 | 189 |
| GO:001623621 | Liver | HCC | macroautophagy | 204/7958 | 291/18723 | 8.66e-22 | 1.41e-19 | 204 |
| GO:190336222 | Liver | HCC | regulation of cellular protein catabolic process | 182/7958 | 255/18723 | 5.91e-21 | 8.52e-19 | 182 |
| GO:002241112 | Liver | HCC | cellular component disassembly | 282/7958 | 443/18723 | 1.02e-19 | 1.38e-17 | 282 |
| GO:003596612 | Liver | HCC | response to topologically incorrect protein | 123/7958 | 159/18723 | 2.60e-19 | 3.44e-17 | 123 |
| GO:190305022 | Liver | HCC | regulation of proteolysis involved in cellular protein catabolic process | 157/7958 | 221/18723 | 5.93e-18 | 6.83e-16 | 157 |
| GO:001050621 | Liver | HCC | regulation of autophagy | 210/7958 | 317/18723 | 7.59e-18 | 8.45e-16 | 210 |
| GO:190332022 | Liver | HCC | regulation of protein modification by small protein conjugation or removal | 167/7958 | 242/18723 | 4.99e-17 | 4.72e-15 | 167 |
| GO:001657021 | Liver | HCC | histone modification | 283/7958 | 463/18723 | 2.68e-16 | 2.33e-14 | 283 |
| GO:006113622 | Liver | HCC | regulation of proteasomal protein catabolic process | 134/7958 | 187/18723 | 5.03e-16 | 4.09e-14 | 134 |
| GO:200005822 | Liver | HCC | regulation of ubiquitin-dependent protein catabolic process | 120/7958 | 164/18723 | 1.31e-15 | 9.74e-14 | 120 |
| GO:000698612 | Liver | HCC | response to unfolded protein | 103/7958 | 137/18723 | 6.50e-15 | 4.48e-13 | 103 |
| GO:190300811 | Liver | HCC | organelle disassembly | 89/7958 | 114/18723 | 8.68e-15 | 5.73e-13 | 89 |
| GO:003243422 | Liver | HCC | regulation of proteasomal ubiquitin-dependent protein catabolic process | 100/7958 | 134/18723 | 3.67e-14 | 2.32e-12 | 100 |
| GO:003596712 | Liver | HCC | cellular response to topologically incorrect protein | 89/7958 | 116/18723 | 5.61e-14 | 3.39e-12 | 89 |
| GO:003139622 | Liver | HCC | regulation of protein ubiquitination | 142/7958 | 210/18723 | 1.39e-13 | 7.81e-12 | 142 |
| GO:003052222 | Liver | HCC | intracellular receptor signaling pathway | 171/7958 | 265/18723 | 3.00e-13 | 1.61e-11 | 171 |
| GO:004854522 | Liver | HCC | response to steroid hormone | 206/7958 | 339/18723 | 6.81e-12 | 2.92e-10 | 206 |
| GO:003462012 | Liver | HCC | cellular response to unfolded protein | 71/7958 | 96/18723 | 3.70e-10 | 1.22e-08 | 71 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| UFL1 | SNV | Missense_Mutation | rs749425862 | c.1609N>G | p.Ile537Val | p.I537V | O94874 | protein_coding | tolerated(0.53) | benign(0.024) | TCGA-A2-A04P-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | taxol | PD |
| UFL1 | SNV | Missense_Mutation | c.1139T>C | p.Met380Thr | p.M380T | O94874 | protein_coding | deleterious(0) | possibly_damaging(0.526) | TCGA-A2-A1FV-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cyclophosphamide | SD | |
| UFL1 | SNV | Missense_Mutation | c.2232N>C | p.Lys744Asn | p.K744N | O94874 | protein_coding | deleterious(0.05) | benign(0.185) | TCGA-AR-A1AI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | PD | |
| UFL1 | SNV | Missense_Mutation | c.1525N>G | p.Leu509Val | p.L509V | O94874 | protein_coding | deleterious(0) | possibly_damaging(0.784) | TCGA-C8-A1HM-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | doxorubicin | CR | |
| UFL1 | SNV | Missense_Mutation | c.1884C>G | p.Asn628Lys | p.N628K | O94874 | protein_coding | tolerated(0.64) | benign(0.003) | TCGA-D8-A1JK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| UFL1 | SNV | Missense_Mutation | c.1309N>A | p.Gly437Arg | p.G437R | O94874 | protein_coding | deleterious(0.01) | possibly_damaging(0.804) | TCGA-E9-A22H-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| UFL1 | SNV | Missense_Mutation | rs777997396 | c.2375N>T | p.Thr792Met | p.T792M | O94874 | protein_coding | deleterious(0.01) | possibly_damaging(0.791) | TCGA-EW-A1IZ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | taxotere | SD |
| UFL1 | insertion | In_Frame_Ins | rs775473285 | c.1752_1753insGAG | p.Leu584_Ile585insGlu | p.L584_I585insE | O94874 | protein_coding | TCGA-BH-A0HN-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | ||
| UFL1 | insertion | In_Frame_Ins | rs762826701 | c.1754_1755insAAG | p.Ile585_Phe586insSer | p.I585_F586insS | O94874 | protein_coding | TCGA-BH-A0HN-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | ||
| UFL1 | SNV | Missense_Mutation | c.1507G>C | p.Glu503Gln | p.E503Q | O94874 | protein_coding | tolerated(0.2) | benign(0.1) | TCGA-UC-A7PF-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |